Characterization of gyrA mutations associated with fluoroquinolone resistance in Campylobacter coli by DNA sequence analysis and MAMA PCR.
Increasing numbers of fluoroquinolone-resistant Campylobacter coli isolates received at the Minnesota State Public Health Laboratory and at the Centers for Disease Control and Prevention have been a cause for concern. The gyrA quinolone resistance-determining regions of several fluoroquinolone-resistant isolates were sequenced to examine the mechanism of resistance. Ciprofloxacin-resistant C. coli isolates examined by DNA sequencing had a Thr-86 to Ile (ACT-->ATT) gyrA mutation, leading to resistance to fluoroquinolone antibiotics. A mismatch amplification mutation assay polymerase chain reaction protocol was developed to detect this gyrA mutation.
Zirnstein
G
G
National Center for Infectious Diseases, Centers for Disease Control and Prevention, US Department of Health and Human Services, Atlanta, GA 30333, USA. gaz3@cdc.gov
Helsel
L
L
Li
Y
Y
Swaminathan
B
B
Besser
J
J
D000890:Anti-Infective Agents / Q000494:pharmacology*; D001483:Base Sequence; D002169:Campylobacter Infections / Q000382:microbiology; D017000:Campylobacter coli / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D002939:Ciprofloxacin / Q000494:pharmacology*; D027081:DNA Gyrase; D004250:DNA Topoisomerases, Type II / Q000235:genetics*; D004352:Drug Resistance, Microbial; D005798:Genes, Bacterial; D006801:Humans; D008826:Microbial Sensitivity Tests; D008969:Molecular Sequence Data; D009154:Mutation; D009268:Nalidixic Acid / Q000494:pharmacology*; D016133:Polymerase Chain Reaction / Q000379:methods; D017422:Sequence Analysis, DNA
D000890:Anti-Infective Agents; D009268:Nalidixic Acid; D002939:Ciprofloxacin; D027081:DNA Gyrase; D004250:DNA Topoisomerases, Type II